The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes
- Disease/Condition
- Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- IDegLira
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Peking University People's Hospital
- Phase
- Phase 4
- Start date
- Apr 30, 2024
- End date
- Feb 28, 2025
- Enrollment
- 256 participants
Hemoglobin A1c (HbA1c)
The study aims to evaluate the efficacy and safety of IDegLira in type 2 diabetes who have
 failed premixed insulin therapy. The study plans to enroll 256 participants with inadequate
 glycemic control despite twice-daily subcutaneous injections of premixed insulin and
 metformin. Participants will be randomly assigned to either the premixed insulin dose
 optimization group (control group) or IDegLira once daily group, and the difference in change
 in glycated hemoglobin levels from baseline to 16 weeks of treatment will be assessed between
 the two groups.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06408532
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06408532 through Pure Global AI's free database. This Phase 4 trial is sponsored by Peking University People's Hospital and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 256 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.